Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil

International Journal of Antimicrobial Agents

Volumn 28, Issue 4, 2006, Pages 340-344

  Kiffer, Carlos R V ^a   Kuti, Joseph L ^b   Eagye, Kathryn J ^b   Mendes, Caio ^a   Nicolau, David P ^b  

^a Fleury   (Brazil)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Carbapenem; Ertapenem; ESBL; Imipenem; Meropenem; Pharmacodynamics

Indexed keywords

ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM;

ARTICLE; BACTERIUM ISOLATE; BRAZIL; CALCULATION; CONTROLLED STUDY; ESCHERICHIA COLI; KLEBSIELLA; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL;

BETA-LACTAMASES; BETA-LACTAMS; BRAZIL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; HUMANS; IMIPENEM; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; THIENAMYCINS;

EID: 33748753836     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.05.031     Document Type: Article

References (22)

1. Bradford P.A. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14 (2001) 933-951
2. Turner P.J. Extended-spectrum beta-lactamases. Clin Infect Dis 41 Suppl. 4 (2005) S273-S275
3. Goossens H., and Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 53 (2005) 257-264
4. Kiffer C., Hsiung A., Oplustil C., et al., the MYSTIC Brazil Group. Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003. Braz J Infect Dis 9 (2005) 214-222
5. Jones R.N. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 24 (2003) 121-134
6. Clark N.M., Patterson J., and Lynch J.P. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care 9 (2003) 413-423
7. Paterson D.L., Mulazimoglu L., Casellas J.M., et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 30 (2000) 473-478
8. Lautenbach E., Strom B.L., Bilker W.B., Patel J.B., Edelstein P.H., and Fishman N.O. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 33 (2001) 1288-1294
9. Gesser R.M., McCarroll K., Teppler H., and Woods G.L. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. J Antimicrob Chemother 51 (2003) 1253-1260
10. Livermore D.M., Oakton K.J., Carter M.W., and Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. Antimicrob Agents Chemother 45 (2001) 2831-2837
11. Livermore D.M., Carter M.W., Bagel S., et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 45 (2001) 1860-1867
12. Moczygemba L.R., Frei C.R., and Burgess D.S. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum β-lactamases. Clin Ther 26 (2004) 1800-1807
13. Jacoby G.A., Mills D.M., and Chow N. Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 48 (2004) 3203-3206
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Fifteenth Informational Supplement. Document M100-S15. Wayne, PA: CLSI; 2005.
15. Pletz M.W., Rau M., Bulitta J., et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 48 (2004) 3765-3772
16. Kuti J., Nightingale C., and Nicolau D. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob Agents Chemother 48 (2004) 2464-2470
17. Mouton J.W., Dudley M.N., Cars O., Derendorf H., and Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55 (2005) 601-607
18. Paterson D.L., Rossi F., Baquero F., et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 55 (2005) 965-973
19. Mendes C., Oplustil C., Sakagami E., Turner P., and Kiffer C. Antimicrobial susceptibility in intensive care units: MYSTIC Program Brazil 2002. Braz J Infect Dis 9 (2005) 42-49
20. Livermore D.M., Sefton A.M., and Scott G.M. Properties and potential of ertapenem. J Antimicrob Chemother 52 (2003) 331-344
21. Mendes C., Kiffer C., Segura A., Ribeiro J., and Turner P. Klebsiella pneumoniae with multiple antimicrobial resistance. Braz J Infect Dis 8 (2004) 109-111
22. Andrade SS, Silva RC, Cayô R, Furtado G, Pignatari AC, Tufik S. Caracterização dos mecanismos de resistência em Klebsiella pneumoniae resistente a carbapenems. In: 39th Congresso Brasileiro de Patologia Clínica/Medicina Laboratorial; 2005 September 17-20; São Paulo, Brazil (abstract P15).